  | Today's Top Story |  |  | | - Biotech startup lands $11M to develop pioneering anticoagulant
Index Ventures has invested $11 million in XO1, a biotech firm established to develop a new kind of anticoagulant that can prevent blood clots without causing bleeding. The drug, called ichorcumab, was created by researchers at University of Cambridge and Addenbrooke's Hospital in the U.K. "This antibody can deliver a high degree of anticoagulation without increased bleeding; we've never seen that before," said a Cambridge professor who helped develop the drug. Yahoo/Reuters (6/16)       | Health Care & Policy | | | | - Don't misuse patents to curb market entry of biosimilars
 Patents help protect the significant investments tied to the development of new drugs and should never be abused to prevent the market entry of legitimate competitors, Edward C. Lawrence writes. Efforts to impede the pathway to biosimilar approval are a brake on innovation and will hurt consumers, Lawrence writes. RxObserver blog (6/13) - Apremilast fares well in psoriatic arthritis trial, Celgene says
A late-stage study found that most psoriatic arthritis patients who took Celgene's investigational drug apremilast experienced significant improvements in signs and symptoms after 52 weeks of treatment. Celgene plans to submit apremilast for both psoriatic arthritis and psoriasis indications in Europe this year. An application has been submitted to the FDA for psoriatic arthritis. PharmaTimes (U.K.) (6/13) - Potential liver toxicity prompts Lilly to stop Alzheimer's drug study
Eli Lilly and Co. has discontinued a Phase II trial of its investigational Alzheimer's disease drug LY2886721, a beta secretase inhibitor, after cases of abnormal liver tests were identified. Lilly believes the liver problems are not linked to how the drug works, and it still wants to develop beta secretase inhibitors for Alzheimer's. Reuters (6/13) - 4 genes turn cells into blood vessel precursors
Researchers at the Icahn School of Medicine at Mount Sinai in New York transferred four genes -- Gata2, Gfi1b, cFos and Etv6 -- into mouse fibroblast cells and were able to create cells that function like hematopoietic stem cells. "The cells that we grew in a petri dish are identical in gene expression to those found in the mouse embryo and could eventually generate colonies of mature blood cells," lead author Carlos Filipe Pereira said. The study was reported in the journal Cell Stem Cell. Yahoo/Asian News International (6/14) | Company & Financial News | | | | - USDA describes biotech wheat found in Ore. as isolated
The Department of Agriculture said the discovery of Monsanto's unapproved biotech wheat at an Oregon field is "a single isolated incident," adding it has not found biotech seeds at fields other than the original site. "As of today, USDA has neither found nor been informed of anything that would indicate that this incident amounts to more than a single isolated incident in a single field on a single farm," the USDA said. Reuters (6/15)  | Analyst brief: Axendia: Lowering the Cost of Healthcare from the Inside Out
Healthcare administrators are seeking ways to manage a mix of Clinical, Biomedical, Facilities, Engineering and Health IT assets. Learn how Healthcare Executives are leveraging an integrated Enterprise Asset Management solution to enhance patient care and improve clinical outcomes, reduce costs and ensure compliance. |
 | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - Iowa ethanol plant moves closer to adding cellulosic system
The Quad County Corn Processors ethanol plant in Galva, Iowa, is planning to begin installing equipment for converting corn fiber into cellulosic ethanol in the next few weeks, with operational status expected by April 2014. Once up and running, the system is expected to deliver 6% more ethanol without needing more feedstock, said Delayne Johnson, the plant's general manager. A side effect of the process, however, is a change in the composition of the distillers grain byproduct, making it something closer to corn gluten meal, Johnson said. Iowa Farmer Today (6/13) | News from BIO | | | | - April 2013 BIO therapeutic newsletters
The BIO Emerging Companies Section Policy Team has compiled the latest news to keep you informed on the action in Washington with respect to the disease category on which your company is focused. Topics covered comprise: Allergy/Infectious Disease/Antiviral; Cardiology/Pulmonology/Blood; Nephrology/Endocrinology/Metabolism/Gastroenterology; Neurology/CNS; Oncology; and Rheumatology/Anesthesia/Inflammation/Pain. BIO has attempted to include updates from biotech stakeholders around Washington, including Congress, FDA, NIH and patient organizations. Access our April 2013 Therapeutic Newsletters. Should you have any comments or questions, please contact Charles Crain.
| SmartQuote | | | |  | I long to accomplish a great and noble task, but it is my chief duty to accomplish small tasks as if they were great and noble."
--Helen Keller,
American writer and political activist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, June 14, 2013
- Thursday, June 13, 2013
- Wednesday, June 12, 2013
- Tuesday, June 11, 2013
- Monday, June 10, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment